Author

Millie Long 1

1 University of North Carolina, Center for Gastrointestinal Biology and Disease,Chapel Hill,United States

An update on the analysis of non-melanoma skin cancer in the tofacitinib ulcerative colitis programme

Bruce E. Sands, Millie Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO ANTI-TUMOR NECROSIS FACTOR AGENT: THE RANDOMIZED, PHASE 3 HICKORY TRIAL

Laurent Peyrin-Biroulet, Ailsa L Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward V Loftus Jr, Elham Ostad-Saffari, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William Sandborn

HISTOLOGICAL INFLAMMATION PREDICTS LOSS OF REMISSION AMONG CROHN’S PATIENTS WITH ENDOSCOPIC REMISSION: A US COHORT ANALYSIS

Janet S. Hildebrand, Julie Crawford, HARRIS AHMAD, Jiyoon Choi, Derek Gazis, James Canavan, Benjamin Click, Millie Long

SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS

Silvio Danese, Millie Long, Elyssa Ott, Christopher Gasink, Thomas Baker, Ye Miao, Ilia Tikhonov, Proton Rahman, Edward V. Loftus, Bruce Strober

Item 1 - 5 / 5
1